Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Study of Real Life Treatment for Multiple Myeloma (MM)

NCT04985643

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Altai Regional Clinical Hospital Barnaul, Altayskiy Kray, Russia

Kaluga Regional Clinical Hospital Kaluga, Central Federal District, Russia

Smolensk Clinical Hospital of Russian Railways-Medicine Smolensk, Central Federal District, Russia

City Clinical Hospital No. 1 named after prof. S.I.Sergeev Khabarovsk, Far Eastern Federal District, Russia

View all 24 locations

View Trial Details

Active, Not Recruiting

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Arkansas for Medical Sciences Little Rock, Arkansas, United States

View Trial Details

Active, Not Recruiting

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT02427620

Conditions: Blastoid Variant Mantle Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

NCT00734877

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy Little Rock, Arkansas, United States

View Trial Details

Active, Not Recruiting

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108

Conditions: Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +23 more
Locations: LSU Health Sciences Center - Shreveport Shreveport, Louisiana, United States

Montefiore Medical Center The Bronx, New York, United States

University of North Carolina Chapel Hill, North Carolina, United States

UC Health Cincinnati, Ohio, United States

View Trial Details

Active, Not Recruiting

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

NCT07153796

Conditions: B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: The University of Texas M. D. Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

NCT04802590

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: A.Z. Sint Jan AV Bruges, Belgium

Universite Libre de Bruxelles - Hopital ERASME Brussels, Belgium

Hopital Jolimont Haine-Saint-Paul, Belgium

CHU de Liege Liège, Belgium

View all 45 locations

View Trial Details

Active, Not Recruiting

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

NCT05944562

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations: Washington University School of Medicine St Louis, Missouri, United States

View Trial Details

Active, Not Recruiting

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

NCT05495464

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

NCT03573700

Conditions: Acute Lymphoblastic Leukemia, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Disease Attributes, +15 more
Locations: St. Jude Children's Research Hospital Memphis, Tennessee, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions